Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 20;123(12):1957-60.
doi: 10.1182/blood-2014-01-547869.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

Holbrook E Kohrt  1 , Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E M Herman, Jonathon P Butchar, Carolyn Cheney, Xiaoli Zhang, Joseph J Buggy, Natarajan Muthusamy, Ronald Levy, Amy J Johnson, John C Byrd
Affiliations

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

Holbrook E Kohrt et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ibrutinib antagonizes antibody-dependent NK cell–mediated cytotoxicity. To evaluate NK cell function, purified NK cells were isolated from healthy peripheral blood mononuclear cells and cultured with 0.1 or 1 μM of ibrutinib for 4 hours together with rituximab-coated (10 µg/mL) lymphoma cells, DHL4, or trastuzumab-coated (10 µg/mL) HER2+ breast cancer cells, HER18, and (A) supernatant was harvested and analyzed by enzyme-linked immunosorbent assay for interferon-γ, and (B) NK cells isolated and analyzed for degranulation by flow cytometry for CD107a mobilization. (C-D) NK cell cytotoxicity as percent lysis of DHL4 or HER18 tumor cells was analyzed in chromium release assays with purified NK cells incubated with (C) chromium-labeled DHL4 or HER18 cells for 4 hours at variable effector:target ratios, rituximab (10 µg/mL), and ibrutinib (0.1 or 1 μM) or (D) chromium-labeled Raji or autologous CLL cells for 4 hours at variable rituximab concentrations at a constant effector:target ratio of 25:1 and ibrutinib (1 μM) or CGI-1746 (1 μM). All in vitro experiments were performed in triplicate. To evaluate NK cell function, in vivo athymic ν/ν mouse models (10 mice per group) were xenotransplated with HER18 or DHL4 tumor cells (1 × 106) subcutaneously along the flank on day 0 and monitored for (E,G,I) tumor growth and (F,H,J) survival with experiments performed in duplicate. (E-F) In vivo therapy of the HER18 tumor model included intraperitoneal (ip) immunoglobulin G (IgG) control on days 4, 8, 12, and 16; ip trastuzumab (200 μg) on days 4, 8, 12, and 16; ibrutinib (25 mg/kg/dose) twice daily on days 4 to 18 by oral gavage (og); or the combination. (G-H) In vivo concurrent therapy of the DHL4 lymphoma model included ip IgG control on days 14, 18, 22, and 26; ip rituximab (200 μg) on days 14, 18, 22, and 26, ibrutinib og (25 mg/kg/dose) twice daily on days 14 to 28; or the combination. (I-J) In vivo sequential versus concurrent therapy of the DHL4 lymphoma model included sequential ibrutinib og (25 mg/kg/dose) twice daily on days 14 to 21 and ip rituximab (200 μg) on days 22 and 26; or sequential ip rituximab (200 μg) on days 14 and 18 and ibrutinib og (25 mg/kg/dose) twice daily on days 21 to 28; or concurrent ip rituximab (200 μg) on days 14, 18, 22, and 26 and ibrutinib og (25 mg/kg/dose) twice daily on days 14 to 28. BID, twice daily.
Figure 1
Figure 1
Ibrutinib antagonizes antibody-dependent NK cell–mediated cytotoxicity. To evaluate NK cell function, purified NK cells were isolated from healthy peripheral blood mononuclear cells and cultured with 0.1 or 1 μM of ibrutinib for 4 hours together with rituximab-coated (10 µg/mL) lymphoma cells, DHL4, or trastuzumab-coated (10 µg/mL) HER2+ breast cancer cells, HER18, and (A) supernatant was harvested and analyzed by enzyme-linked immunosorbent assay for interferon-γ, and (B) NK cells isolated and analyzed for degranulation by flow cytometry for CD107a mobilization. (C-D) NK cell cytotoxicity as percent lysis of DHL4 or HER18 tumor cells was analyzed in chromium release assays with purified NK cells incubated with (C) chromium-labeled DHL4 or HER18 cells for 4 hours at variable effector:target ratios, rituximab (10 µg/mL), and ibrutinib (0.1 or 1 μM) or (D) chromium-labeled Raji or autologous CLL cells for 4 hours at variable rituximab concentrations at a constant effector:target ratio of 25:1 and ibrutinib (1 μM) or CGI-1746 (1 μM). All in vitro experiments were performed in triplicate. To evaluate NK cell function, in vivo athymic ν/ν mouse models (10 mice per group) were xenotransplated with HER18 or DHL4 tumor cells (1 × 106) subcutaneously along the flank on day 0 and monitored for (E,G,I) tumor growth and (F,H,J) survival with experiments performed in duplicate. (E-F) In vivo therapy of the HER18 tumor model included intraperitoneal (ip) immunoglobulin G (IgG) control on days 4, 8, 12, and 16; ip trastuzumab (200 μg) on days 4, 8, 12, and 16; ibrutinib (25 mg/kg/dose) twice daily on days 4 to 18 by oral gavage (og); or the combination. (G-H) In vivo concurrent therapy of the DHL4 lymphoma model included ip IgG control on days 14, 18, 22, and 26; ip rituximab (200 μg) on days 14, 18, 22, and 26, ibrutinib og (25 mg/kg/dose) twice daily on days 14 to 28; or the combination. (I-J) In vivo sequential versus concurrent therapy of the DHL4 lymphoma model included sequential ibrutinib og (25 mg/kg/dose) twice daily on days 14 to 21 and ip rituximab (200 μg) on days 22 and 26; or sequential ip rituximab (200 μg) on days 14 and 18 and ibrutinib og (25 mg/kg/dose) twice daily on days 21 to 28; or concurrent ip rituximab (200 μg) on days 14, 18, 22, and 26 and ibrutinib og (25 mg/kg/dose) twice daily on days 14 to 28. BID, twice daily.
See this image and copyright information in PMC

References

    1. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. - PMC - PubMed
    1. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549. - PMC - PubMed
    1. Khurana D, Arneson LN, Schoon RA, Dick CJ, Leibson PJ. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol. 2007;178(6):3575–3582. - PubMed
    1. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635–2642. - PubMed
    1. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423–2432. - PMC - PubMed

Publication types

MeSH terms